Experimental treatment strategies in primary cutaneous T cell lymphomas
Purpose of review Cutaneous T cell lymphoma (CTCL) comprises a heterogeneous group of malignancies derived from skin homing or resident T cells. Effective treatments are limited, thus new therapies are in development to address the unmet medical need. Recent findings Recent studies uncovering the genetic alteration in cutaneous T cell lymphoma have enhanced our understanding of the importance of the T cell activation/survival pathways, dysregulated immune system, and the relevance of chromatin modification in the pathogenesis of CTCL. New advances in cancer immunomodulation such as with PD1/PD L1 inhibitors and novel targeted antitumor therapies such as brentuximab vedotin and mogamulizumab as well as potential combination strategies are promising for improving clinical efficacy with manageable toxicity profile. Summary All these new therapeutic approaches have resulted in broadening the treatment landscape and a potential paradigm shift in the management of CTCL.
Current opinion in oncology